Dr. Mark G. Goldstein, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Baltimore University School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 605
Licensed in Connecticut since 2005, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: Baltimore University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MD license D0067691 · PA license MD438212 -
Internal Medicine Physician
CT license 043952 (first issued 2005; inactive) -
Medical Oncology Physician
MD license D67691
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Suburban Hospital Bethesda, MD
Medical groups
- Maryland Oncology Hematology PA (104 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 605
- Services billed
- 82,437
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 28,050 | 27 |
| Injection, ferric derisomaltose, 10 mg | 3,400 | 30 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,100 | 16 |
| Established patient office or other outpatient visit, 30-39 minutes | 827 | 258 |
| Insertion of needle into vein for collection of blood sample | 809 | 232 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 807 | 220 |
| Established patient office or other outpatient visit, 20-29 minutes | 486 | 293 |
| Injection of additional new drug or substance into vein | 247 | 24 |
| Administration of chemotherapy into vein, 1 hour or less | 153 | 19 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 130 | 64 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Germantown, MD | 102 |
| Xarelto (rivaroxaban) Other prescribers in Germantown, MD | 36 |
| Dexamethasone Other prescribers in Germantown, MD | 29 |
| Prednisone Other prescribers in Germantown, MD | 26 |
| Hydroxyurea Other prescribers in Germantown, MD | 23 |
| Letrozole Other prescribers in Germantown, MD | 20 |
| Ondansetron Hcl Other prescribers in Germantown, MD | 18 |
| Erleada (apalutamide) | 17 |
| Prochlorperazine Maleate Other prescribers in Germantown, MD | 16 |
| Promacta (eltrombopag olamine) | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 48 companies reported 125 payments worth $3,623 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $370 |
|---|---|
| Janssen Biotech, Inc. | $265 |
| Merck Sharp & Dohme LLC | $245 |
| Daiichi Sankyo Inc. | $194 |
| Beone Medicines USA, Inc. | $176 |
| AstraZeneca Pharmaceuticals LP | $150 |
| Tempus Ai, Inc | $149 |
| Genzyme Corporation | $123 |
| Food and Beverage | $3,623 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $217,194 in research payments for these studies, mostly to the institutions running them.
- A Phase III, double-blind, placebo-controlled, Randomized, Multicenter, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced Stage III, Unresectable Non-sm…
AstraZeneca Pharmaceuticals LP - A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Pros…
AstraZeneca UK Limited - A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Ca…
AstraZeneca Pharmaceuticals LP - A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer ARTEMIDE-Lu…
AstraZeneca Pharmaceuticals LP - A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors
Amgen Inc. - Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Aadi Bioscience, Inc. · Completed · NCT05103358 - A phase 3, open-label, randomized study of perioperative dostarlimab m
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.